The short version of IGF-1 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-11 and is reviewed periodically as new material appears.
Measured responses usually involve growth hormone and insulin-like growth factor 1, known as IGF-1. Growth hormone rises in bursts and is difficult to sample reliably, while IGF-1 shifts more slowly and can be assessed from a single blood draw. Studies therefore treat IGF-1 as the more practical pharmacodynamic marker. Both are indirect, showing that the receptor was engaged rather than that the peptide reached a particular concentration. Direct exposure measurement requires an assay aimed at the molecule itself.
Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.
Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.
Whether the drug improves hard clinical outcomes is not settled. No completed trial has shown a reduction in heart attacks or strokes among treated patients, although a dedicated cardiovascular outcomes study has been discussed in the literature. Investigators have also examined hepatic fat in people with HIV and fatty liver disease, cognitive measures in small cohorts, and changes in bone density. Regulatory labeling emphasizes monitoring of insulin-like growth factor 1 because supraphysiologic levels raise questions about tissue growth, and the clinical significance of that signal remains an open question rather than a demonstrated harm.
Binding of tesamorelin to the growth hormone-releasing hormone receptor on anterior pituitary somatotrophs activates a Gs protein pathway, raises cyclic AMP, and triggers release of stored growth hormone into the bloodstream. Because the analogue resists dipeptidyl peptidase-4, its plasma residence time exceeds that of native GHRH, producing a larger and more sustained secretory signal. The released growth hormone then acts on the liver and peripheral tissues to raise insulin-like growth factor 1, which feeds back on the hypothalamus and pituitary. This axis explains both the intended effects on fat distribution and the biological markers used to track them.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | Located on pituitary somatotroph cells |
| Signaling route | cAMP–protein kinase A | Gs-coupled receptor pathway |
| Downstream markers | Growth hormone and IGF-1 | Used as pharmacodynamic readouts |
| Common detection | LC-MS/MS | Separates intact peptide from fragments |
| Typical storage | 2–8 °C, protected from light | Applies to solid form before reconstitution |
Before this, they either had to perform surgery while the patient dealt with the pain, intoxicated, or they needed to knock the patient out unconscious. Apartment blocks – The Ancestral Pueblo people and other tribes which once thrived in the present day Southwest of the US, developed complex multistory apartment complexes, some of which are still in use today. Pueblo communities in present-day New Mexico continue to reside in some of these ancient multistory apartment complexes–which were constructed by their ancestors many centuries ago–even before the first apartments were built in the United States during the 18th century. Pueblo Bonito, one of the seminal archaeological sites today, is an example of this indigenous multistory apartment complex construction from the Anasazi and Hohokam time periods; approximately dating back one thousand years ago.
=== EC 2.7.1: Phosphotransferases with an alcohol group as acceptor === EC 2.7.1.1: hexokinase EC 2.7.1.2: glucokinase EC 2.7.1.3: ketohexokinase EC 2.7.1.4: fructokinase EC 2.7.1.5: rhamnulokinase EC 2.7.1.6: galactokinase EC 2.7.1.7: mannokinase EC 2.7.1.8: glucosamine kinase EC 2.7.1.9: deleted EC 2.7.1.10: phosphoglucokinase EC 2.7.1.11: 6-phosphofructokinase EC 2.7.1.12: gluconokinase EC 2.7.1.13: dehydrogluconokinase EC 2.7.1.14: sedoheptulokinase EC 2.7.1.15: ribokinase EC 2.7.1.16: ribulokinase EC 2.7.1.17: xylulokinase EC 2.7.1.18: phosphoribokinase EC 2.7.1.19: phosphoribulokinase EC 2.7.1.20: adenosine kinase EC 2.7.1.21: thymidine kinase EC 2.7.1.22: ribosylnicotinamide kinase EC 2.7.1.23: NAD+ kinase EC 2.7.1.24: dephospho-CoA kinase EC 2.7.1.25: adenylyl-sulfate kinase EC 2.7.1.26: riboflavin kinase EC 2.7.1.27: erythritol kinase (D-erythritol 4-phosphate-forming) EC 2.7.1.28: triokinase EC 2.7.1.29: glycerone kinase EC 2.7.1.30: glycerol kinase EC 2.7.1.31: glycerate kinase EC 2.7.1.32: choline kinase EC 2.7.1.33: pantothenate kinase EC 2.7.1.34: pantetheine kinase EC 2.7.1.35: pyridoxal kinase EC 2.7.1.36: mevalonate kinase EC 2.7.1.37: now divided into EC 2.7.11.1, EC 2.7.11.8, EC 2.7.11.9, EC 2.7.11.10, EC 2.7.11.11, EC 2.7.11.12, EC 2.7.11.13, EC 2.7.11.21, EC 2.7.11.22, EC 2.7.11.24, EC 2.7.11.25, EC 2.7.11.30 and EC 2.7.12.1 EC 2.7.1.38: now EC 2.7.11.19, phosphorylase kinase EC 2.7.1.39: homoserine kinase EC 2.7.1.40: pyruvate kinase EC 2.7.1.41: glucose-1-phosphate phosphodismutase EC 2.7.1.42: riboflavin phosphotransferase EC 2.7.1.43: glucuronokinase EC 2.7.1.44: galacturonokinase EC 2.7.1.45: 2-dehydro-3-deoxygluconokinase EC 2.7.1.46: L-arabinokinase EC 2.7.1.47: D-ribulokinase EC 2.7.1.48: uridine kinase EC 2.7.1.49: hydroxymethylpyrimidine kinase EC 2.7.1.50: hydroxyethylthiazole kinase EC 2.7.1.51: L-fuculokinase EC 2.7.1.52: fucokinase EC 2.7.1.53: L-xylulokinase EC 2.7.1.54: D-arabinokinase EC 2.7.1.55: allose kinase EC 2.7.1.56: 1-phosphofructokinase EC 2.7.1.57: deleted EC 2.7.1.58: 2-dehydro-3-deoxygalactonokinase EC 2.7.1.59: N-acetylglucosamine kinase EC 2.7.1.60: N-acylmannosamine kinase EC 2.7.1.61: acyl-phosphate—hexose phosphotransferase EC 2.7.1.62: Phosphoramidate-hexose phosphotransferase EC 2.7.1.63: polyphosphate—glucose phosphotransferase EC 2.7.1.64: inositol 3-kinase EC 2.7.1.65: scyllo-inosamine 4-kinase EC 2.7.1.66: undecaprenol kinase EC 2.7.1.67: 1-phosphatidylinositol 4-kinase EC 2.7.1.68: 1-phosphatidylinositol-4-phosphate 5-kinase EC 2.7.1.69: now covered by EC 2.7.1.191, EC 2.7.1.192, EC 2.7.1.193, EC 2.7.1.194, EC 2.7.1.195, EC 2.7.1.196, EC 2.7.1.197, EC 2.7.1.198, EC 2.7.1.199, EC 2.7.1.200 EC 2.7.1.20, EC 2.7.1.202, EC 2.7.1.203, EC 2.7.1.204, EC 2.7.1.205, EC 2.7.1.206, EC 2.7.1.207 and EC 2.7.1.208 EC 2.7.1.70: Now included in EC 2.7.11.1, non-specific serine/threonine protein kinase EC 2.7.1.71: shikimate kinase EC 2.7.1.72: streptomycin 6-kinase EC 2.7.1.73: inosine kinase EC 2.7.1.74: deoxycytidine kinase EC 2.7.1.75: Now EC 2.7.1.21 thymidine kinase EC 2.7.1.76: deoxyadenosine kinase EC 2.7.1.77: nucleoside phosphotransferase EC 2.7.1.78: polynucleotide 5′-hydroxyl-kinase EC 2.7.1.79: diphosphate—glycerol phosphotransferase EC 2.7.1.80: diphosphate—serine phosphotransferase EC 2.7.1.81: hydroxylysine kinase EC 2.7.1.82: ethanolamine kinase EC 2.7.1.83: pseudouridine kinase EC 2.7.1.84: alkylglycerone kinase EC 2.7.1.85: β-glucoside kinase EC 2.7.1.86: NADH kinase EC 2.7.1.87: streptomycin 3′′-kinase EC 2.7.1.88: dihydrostreptomycin-6-phosphate 3′α-kinase EC 2.7.1.89: thiamine kinase EC 2.7.1.90: diphosphate—fructose-6-phosphate 1-phosphotransferase EC 2.7.1.91: sphinganine kinase EC 2.7.1.92: 5-dehydro-2-deoxygluconokinase EC 2.7.1.93: alkylglycerol kinase EC 2.7.1.94: acylglycerol kinase EC 2.7.1.95: kanamycin kinase EC 2.7.1.96: deleted, Now included with EC 2.7.1.86 NADH kinase EC 2.7.1.97: deleted, Identical with EC 2.7.11.14, rhodopsin kinase EC 2.7.1.98: deleted EC 2.7.1.99: Now EC 2.7.11.2, [pyruvate dehydrogenase (acetyl-transferring)] kinase EC 2.7.1.100: S-methyl-5-thioribose kinase EC 2.7.1.101: tagatose kinase EC 2.7.1.102: hamamelose kinase EC 2.7.1.103: viomycin kinase EC 2.7.1.104: Now EC 2.7.99.1, triphosphate—protein phosphotransferase EC 2.7.1.105: 6-phosphofructo-2-kinase EC 2.7.1.106: glucose-1,6-bisphosphate synthase EC 2.7.1.107: diacylglycerol kinase EC 2.7.1.108: dolichol kinase EC 2.7.1.109: Now EC 2.7.11.31, [hydroxymethylglutaryl-CoA reductase (NADPH)] kinase EC 2.7.1.110: Now EC 2.7.11.3, dephospho-(reductase kinase) kinase EC 2.7.1.111: Now listed as EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.112: Now EC 2.7.10.2, non-specific protein-tyrosine kinase EC 2.7.1.113: deoxyguanosine kinase EC 2.7.1.114: AMP—thymidine kinase EC 2.7.1.115: Now EC 2.7.11.4, (3-methyl-2-oxobutanoate dehydrogenase (acetyl-transferring)) kinase EC 2.7.1.116: Now EC 2.7.11.5, [isocitrate dehydrogenase (NADP+)] kinase EC 2.7.1.117: Now EC 2.7.11.18, myosin-light-chain kinase EC 2.7.1.118: ADP—thymidine kinase EC 2.7.1.119: hygromycin-B 7′′-O-kinase EC 2.7.1.120: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.121: phosphoenolpyruvate—glycerone phosphotransferase EC 2.7.1.122: xylitol kinase EC 2.7.1.123: Now EC 2.7.11.17, Ca2+/calmodulin-dependent protein kinase EC 2.7.1.124: Now EC 2.7.11.6, [tyrosine 3-monooxygenase] kinase EC 2.7.1.125: Now EC 2.7.11.14, rhodopsin kinase EC 2.7.1.126: Now EC 2.7.11.15, β-adrenergic-receptor kinase EC 2.7.1.127: inositol-trisphosphate 3-kinase EC 2.7.1.128: Now EC 2.7.11.27, [acetyl-CoA carboxylase] kinase EC 2.7.1.129: Now EC 2.7.11.7, myosin-heavy-chain kinase EC 2.7.1.130: tetraacyldisaccharide 4′-kinase EC 2.7.1.131: Now EC 2.7.11.29, low-density-lipoprotein receptor kinase EC 2.7.1.132: Now EC 2.7.11.28, tropomyosin kinase EC 2.7.1.133: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.134: inositol-tetrakisphosphate 1-kinase EC 2.7.1.135: Now EC 2.7.11.26, tau-protein kinase EC 2.7.1.136: macrolide 2′-kinase EC 2.7.1.137: phosphatidylinositol 3-kinase EC 2.7.1.138: ceramide kinase EC 2.7.1.139: Now included with EC 2.7.1.134, inositol-tetrakisphosphate 1-kinase EC 2.7.1.140: inositol-tetrakisphosphate 5-kinase EC 2.7.1.141: Now EC 2.7.11.23, [RNA-polymerase]-subunit kinase EC 2.7.1.142: glycerol-3-phosphate—glucose phosphotransferase EC 2.7.1.143: diphosphate-purine nucleoside kinase EC 2.7.1.144: tagatose-6-phosphate kinase EC 2.7.1.145: deoxynucleoside kinase EC 2.7.1.146: ADP-dependent phosphofructokinase EC 2.7.1.147: ADP-dependent glucokinase EC 2.7.1.148: 4-(cytidine 5′-diphospho)-2-C-methyl-D-erythritol kinase EC 2.7.1.149: 1-phosphatidylinositol-5-phosphate 4-kinase EC 2.7.1.150: 1-phosphatidylinositol-3-phosphate 5-kinase EC 2.7.1.151: inositol-polyphosphate multikinase EC 2.7.1.152: Now EC 2.7.4.21, inositol-hexakisphosphate kinase EC 2.7.1.153: phosphatidylinositol-4,5-bisphosphate 3-kinase EC 2.7.1.154: phosphatidylinositol-4-phosphate 3-kinase EC 2.7.1.155: Now EC 2.7.4.24, diphosphoinositol-pentakisphosphate kinase EC 2.7.1.156: adenosylcobinamide kinase EC 2.7.1.157: N-acetylgalactosamine kinase EC 2.7.1.158: inositol-pentakisphosphate 2-kinase EC 2.7.1.159: inositol-1,3,4-trisphosphate 5/6-kinase EC 2.7.1.160: 2′-phosphotransferase EC 2.7.1.161: CTP-dependent riboflavin kinase EC 2.7.1.162: N-acetylhexosamine 1-kinase EC 2.7.1.163: hygromycin B 4-O-kinase EC 2.7.1.164: O-phosphoseryl-tRNASec kinase EC 2.7.1.165: glycerate 2-kinase EC 2.7.1.166: 3-deoxy-D-manno-octulosonic acid kinase EC 2.7.1.167: D-glycero-β-D-manno-heptose-7-phosphate kinase EC 2.7.1.168: D-glycero-α-D-manno-heptose-7-phosphate kinase EC 2.7.1.169: pantoate kinase EC 2.7.1.170: anhydro-N-acetylmuramic acid kinase EC 2.7.1.171: protein-fructosamine 3-kinase EC 2.7.1.172: protein-ribulosamine 3-kinase EC 2.7.1.173: nicotinate riboside kinase EC 2.7.1.174: diacylglycerol kinase (CTP dependent) EC 2.7.1.175: maltokinase EC 2.7.1.176: UDP-N-acetylglucosamine kinase EC 2.7.1.177: L-threonine kinase EC 2.7.1.178: 2-dehydro-3-deoxyglucono/galactono-kinase EC 2.7.1.179: kanosamine kinase EC 2.7.1.180: FAD:protein FMN transferase EC 2.7.1.181: polymannosyl GlcNAc-diphospho-ditrans,octacis-undecaprenol kinase EC 2.7.1.182: phytol kinase EC 2.7.1.183: glycoprotein-mannosyl O6-kinase EC 2.7.1.184: sulfofructose kinase EC 2.7.1.185: mevalonate 3-kinase EC 2.7.1.186: mevalonate-3-phosphate 5-kinase EC 2.7.1.187: acarbose 7IV-phosphotransferase EC 2.7.1.188: 2-epi-5-epi-valiolone 7-kinase EC 2.7.1.189: autoinducer-2 kinase EC 2.7.1.190: aminoglycoside 2′′-phosphotransferase EC 2.7.1.191: protein-N π-phosphohistidine—D-mannose phosphotransferase EC 2.7.1.192: protein-N π-phosphohistidine—N-acetylmuramate phosphotransferase EC 2.7.1.193: protein-N π-phosphohistidine—N-acetyl-D-glucosamine phosphotransferase EC 2.7.1.194: protein-N π-phosphohistidine—L-ascorbate phosphotransferase EC 2.7.1.195: protein-N π-phosphohistidine—2-O-α-mannosyl-D-glycerate phosphotransferase EC 2.7.1.196: protein-N π-phosphohistidine—N,N′-diacetylchitobiose phosphotransferase EC 2.7.1.197: protein-Nπ'-phosphohistidine—D-mannitol phosphotransferase EC 2.7.1.198: protein-N π-phosphohistidine—D-sorbitol phosphotransferase EC 2.7.1.199: protein-N π-phosphohistidine—D-glucose phosphotransferase EC 2.7.1.200: protein-N π-phosphohistidine—galactitol phosphotransferase EC 2.7.1.201: protein-N π-phosphohistidine—trehalose phosphotransferase EC 2.7.1.202: protein-N π-phosphohistidine—D-fructose phosphotransferase EC 2.7.1.203: protein-N π-phosphohistidine—D-glucosaminate phosphotransferase EC 2.7.1.204: protein-N π-phosphohistidine—D-galactose phosphotransferase EC 2.7.1.205: protein-N π-phosphohistidine—cellobiose phosphotransferase EC 2.7.1.206: protein-N π-phosphohistidine—L-sorbose phosphotransferase EC 2.7.1.207: protein-N π-phosphohistidine—lactose phosphotransferase EC 2.7.1.208: protein-N π-phosphohistidine—maltose phosphotransferase EC 2.7.1.209: L-erythrulose 1-kinase EC 2.7.1.210: D-erythrulose 4-kinase EC 2.7.1.211: protein-N π-phosphohistidine—sucrose phosphotransferase EC 2.7.1.212: α-D-ribose-1-phosphate 5-kinase (ADP) EC 2.7.1.213: cytidine kinase EC 2.7.1.214: C7-cyclitol 7-kinase EC 2.7.1.215: erythritol kinase (D-erythritol 1-phosphate-forming) EC 2.7.1.216: farnesol kinase EC 2.7.1.217: 3-dehydrotetronate 4-kinase EC 2.7.1.218: fructoselysine 6-kinase EC 2.7.1.219: D-threonate 4-kinase EC 2.7.1.220: D-erythronate 4-kinase EC 2.7.1.221: N-acetylmuramate 1-kinase EC 2.7.1.222: 4-hydroxytryptamine kinase EC 2.7.1.223: aminoimidazole riboside kinase EC 2.7.1.224: cytidine diphosphoramidate kinase EC 2.7.1.225: L-serine kinase (ATP) EC 2.7.1.226: L-serine kinase (ADP) EC 2.7.1.227: inositol phosphorylceramide synthase EC 2.7.1.228: mannosyl-inositol-phosphoceramide inositolphosphotransferase EC 2.7.1.229: deoxyribokinase EC 2.7.1.230: amicoumacin kinase EC 2.7.1.231: 3-oxoisoapionate kinase EC 2.7.1.232: levoglucosan kinase EC 2.7.1.233: apulose kinase
=== Otto Mostyn === Otto Mostyn (Roger Barclay) is Henry's godfather, and a fellow classmate of Charles Hanani from Oxford alongside Norton. A sinister, calculating businessman, Otto takes interest in Harper due to her cunning and ruthlessness, and agrees to provide seed funding to LeviathanAlpha, the hedge fund she is starting with Petra Koenig. Otto, Norton, and Aurore are also in a secret cabal to advance their interests via the government. Petra calls Otto after learning that Harper committed insider trading by acting on confidential information she overheard to short Pierpoint. Otto summons Harper to a meeting, where instead of reprimanding her, he tells her he wants her to succeed him in running his investment fund. Harper and Petra ultimately decide to call off the short and end their partnership with Otto to keep their fund above-board, but Harper later teams up with Otto to start her own fund dedicated to shorting corrupt companies over whom she and Otto would have leverage. In series 4, Otto becomes a member of the House of Lords and hopes to obtain a peerage. He puts increasingly strict constraints on Harper's trades at his fund, not wanting her to jeopardize his political connections; she eventually cuts ties with Otto. At Henry's 40th birthday party, Otto receives oral sex from Cordelia, Yasmin's aunt and Charles' sister; it is revealed he also received sexual favors from Charles.
=== Variations and accessories === Bottles may be designed to attach directly to a breast pump for a complete "feeding system" that maximizes the reuse of the components. Such systems include a variety of drinking spouts for when the child is older. This converts the bottle into a sippy cup, a cup with lid and spout for toddlers, which is intermediate between a baby bottle and an open top cup. Bottles that are part of a feeding system may include handles that can be attached. The ring and teat may be replaced by a storage lid. Accessories for bottles include cleaning brushes, or bottle brushes, sterilizers, and drying racks. Brushes may be specially designed for a specific manufacturer's bottles and teats. Bottle sterilizers use different techniques for sterilization, including ultraviolet light, boiling water, and hot steam.
== External links == Lesch-Nyhan Syndrome at NIH's Office of Rare Diseases GeneReview/NIH/UW entry on Lesch–Nyhan syndrome National Institute of Child Health and Human Development (NICHD) Love Never Sinks • Lesch Nyhan• Patient Advocacy Group
Sources: en.wikipedia.org
In the East, the Soviet Union had installed dictatorial governments, controlling East Germany, and the rest of Eastern Europe. Although Stalin died in 1953 and the new general secretary Nikita Khrushchev had denounced him in 1956, Soviet tanks crushed a democratic Hungarian Revolution of 1956, and repressed every other attempt of its people to win democracy and human rights.
=== Public security === The Federal Government presented a proposed constitutional amendment (PEC) aimed at modernizing and integrating public security in the country. The initiative, led by the ministry of justice and public security, Ricardo Lewandowski, seeks to strengthen the fight against organized crime and improve cooperation among the Union, states and municipalities. Among the main points are the creation of a Unified Public Security System (SUSP) with constitutional status, the expansion of the responsibilities of the Federal Police and the Federal Highway Police – which would be renamed the Federal Ostensive Police – and the consolidation of permanent financial instruments, such as the National Public Security and Penitentiary Policy Fund, guaranteeing stable resources for the sector. The government argues that the proposal does not remove the autonomy of the states, but seeks to promote greater coordination and efficiency in police action, especially in the face of the advance of criminal factions operating beyond state borders. Even so, the text faces resistance from sectors of the right and the opposition. Despite the criticism, the Ministry of Justice states that the proposal was built in dialogue with governors and specialists, and that it represents an effort to make the fight against crime more integrated, technological and effective throughout the national territory.
=== Presbyopia === In 2025, the U.S. Food and Drug Administration (FDA) approved aceclidine 1.44 % ophthalmic solution (Vizz) for the topical treatment of presbyopia. The treatment involves a once-daily application to constrict the pupil, creating a pinhole effect that increases the depth of focus and improves near vision. Data from the Clarity 1 and 2 clinical trials showed that the administration of aceclidine resulted in a statistically significant improvement in near visual acuity within approximately 30 minutes, with a duration of effect of up to 8–10 hours. Distance vision was not significantly affected due to the drug's limited action on the ciliary muscle. No serious adverse events were reported in the trials. Common side effects included transient ocular irritation, mild headache, and reduced vision in low-light conditions. Aceclidine became the second pharmacological agent approved for presbyopia in the U.S., following a pilocarpine-based product approved in 2021.
=== Remediation === Algae has shown selectivity for strontium in studies, where most plants used in bioremediation have not shown selectivity between calcium and strontium, often becoming saturated with calcium, which is greater in quantity and also present in nuclear waste. Researchers have looked at the bioaccumulation of strontium by Scenedesmus spinosus (algae) in simulated wastewater. The study claims a highly selective biosorption capacity for strontium of S. spinosus, suggesting that it may be appropriate for use of nuclear wastewater. A study of the pond alga Closterium moniliferum using stable strontium found that varying the ratio of barium to strontium in water improved strontium selectivity.
=== Skeleton === Sex hormones play an important role in bone growth and maintenance. The effects of hormone therapy on bone health are not fully understood, and may depend on whether hormone therapy is started before or after puberty. Bone density continue to grow and change over time. Significant changes to bone structure have been observed, and transgender women have statistically poorer bone health even before beginning the transition process, possibly due to a lack of physical exercise or other risk factors such as low vitamin D, eating disorders, and substance abuse. Approximately 14% of transgender women suffer from osteoporosis. Transgender women below the age of 50 show increased fracture risk compared to age-matched cisgender women, equal to the risk to cisgender men of equivalent age. Transgender women above the age of 50 have a similar fracture risk to post-menopausal women — higher than that of age-matched cis men. In both cases, trans women's fracture patterns follow that of cis women, suffering long-term stress fractures concentrated in the hip, spine, and arms, typical of chronic low bone mineral density, rather than the fracture patterns typical of external injury suffered by cis men. Current clinical guidelines are for bone health to be monitored regularly throughout the transition process, particularly if risk factors are present. Transgender individuals are encouraged to ingest at least 1g of Calcium and 1000 IU of Vitamin D daily, engage regularly in weight-bearing physical activity, and reduce alcohol and smoking consumption.
Sources: en.wikipedia.org
Neurological manifestations can include tremors, chorea, myopathy, and in some susceptible individuals (in particular of Asian descent) periodic paralysis. An association between thyroid disease and myasthenia gravis has been recognized. Thyroid disease, in this condition, is autoimmune in nature, and approximately 5% of people with myasthenia gravis also have hyperthyroidism. Myasthenia gravis rarely improves after thyroid treatment and the relationship between the two entities is becoming better understood over the past 15 years.In Graves' disease, ophthalmopathy may cause the eyes to look enlarged because the eye muscles swell and push the eye forward. Sometimes, one or both eyes may bulge. Some have swelling of the front of the neck from an enlarged thyroid gland (a goiter). Minor ocular (eye) signs, which may be present in any type of hyperthyroidism, are eyelid retraction ("stare"), extraocular muscle weakness, and lid-lag. In hyperthyroid stare (Dalrymple sign) the eyelids are retracted upward more than normal (the normal position is at the superior corneoscleral limbus, where the "white" of the eye begins at the upper border of the iris). Extraocular muscle weakness may present with double vision. In lid-lag (von Graefe's sign), when the person tracks an object downward with their eyes, the eyelid fails to follow the downward-moving iris, and the same type of upper globe exposure which is seen with lid retraction occurs, temporarily. These signs disappear with treatment of the hyperthyroidism.
Source: When tendons are injured, tendon cells are activated to promote repair, but this process can be slow. Recent research has focused on improving tendon healing through therapies such as stem cell injections, growth factors, and tissue-engineered approaches to enhance tendon cell activity and regeneration.
== Chemistry == Dexamethasone is a synthetic pregnane corticosteroid and derivative of cortisol (hydrocortisone) and is also known as 1-dehydro-9α-fluoro-16α-methylhydrocortisone or as 9α-fluoro-11β,17α,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione. The molecular and crystal structure of dexamethasone has been determined by X-ray crystallography. It is a stereoisomer of betamethasone, the two compounds differing only in the spatial configuration of the methyl group at position 16 (see steroid nomenclature).
Carey (1940), executive officer of the American Association for the Advancement of Science and publisher of Science 1975–1987 Robert Bleiberg (1943), former publisher and managing editor of Barron's Gilman Kraft (1947), former owner and publisher of Playbill Jason Epstein (1949), editorial director of Random House and co-founder of the New York Review of Books Bernard Shir-Cliff (1949), editor of Ballantine Books and Warner Books Arthur Ochs Sulzberger (1951), publisher of The New York Times Lee Guittar (1953), former publisher of the San Francisco Examiner, The Denver Post, Dallas Times Herald, and president of USA Today Richard Goodwin Capen, Jr. (1956), former publisher of the Miami Herald; U.S. ambassador to Spain 1992–1993 Peter Mayer (1956), publisher of Overlook Press and former CEO of Penguin Books Daniel Leab (1957), historian, antiquarian and publisher book catalogues, former editor of Labor History Donald Welsh (1965), founding publisher of outdoors magazine Outside Albert Scardino (1970), publisher of The Georgia Gazette and Pulitzer Prize winner in 1984 Louis Rossetto (1971), founder and publisher of Wired magazine David Rothkopf (1977), CEO and editor of Foreign Policy magazine John R. MacArthur (1978), president and publisher of Harper's magazine, grandson of billionaire John D. MacArthur, benefactor of the MacArthur Fellows Program Jake Dobkin (1998), co-founder and publisher of Gothamist franchise
Sources: en.wikipedia.org
It acts on the growth hormone–releasing hormone receptor, a Gs-coupled receptor found on pituitary somatotroph cells. Activation raises cAMP and prompts pulsatile hormone release.
IGF-1 reflects growth hormone activity but changes slowly and can be measured from one sample. Growth hormone itself is pulsatile, which makes single measurements hard to interpret.
The receptor pathway is well described, but how individual responses vary and what governs long-term outcomes remain open questions. Reported differences across studies are often attributed to assay and population factors.
It mimics a natural hypothalamic signal that tells the pituitary to release growth hormone. The result is a rise in circulating growth hormone and, indirectly, in insulin-like growth factor 1. Over weeks of treatment this shift is associated with a selective decrease in fat stored inside the abdomen.